Home › Funds › GILEAD SCIENCES, INC. › RCUS
GILEAD SCIENCES, INC. position in RCUS
ARCUS BIOSCIENCES INC · Health Care
GILEAD SCIENCES, INC. reported holding 31,424,760 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$811.7M, representing 55.45% of its reported portfolio and ranking #1 among its reported holdings. GILEAD SCIENCES, INC. has disclosed RCUS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How GILEAD SCIENCES, INC.'s RCUS position evolved
GILEAD SCIENCES, INC. first disclosed a stake in RCUS in Q4 2024 at 30,061,124 shares (US$447.6M). The position peaked in Q2 2026 at 31,424,760 shares, worth US$968.8M. Across 8 filings, GILEAD SCIENCES, INC. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 31,424,760 shares valued at US$811.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 30.06M | $447.61M | New |
| Q1 2025 | 31.42M | $246.68M | Add |
| Q2 2025 | 31.42M | $255.80M | Hold |
| Q3 2025 | 31.42M | $427.38M | Hold |
| Q4 2025 | 31.42M | $748.85M | Hold |
| Q1 2026 | 31.42M | $678.77M | Hold |
| Q2 2026 | 31.42M | $968.83M | Hold |
| Q3 2026 | 31.42M | $811.70M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 46 other funds we track also report a position in RCUS — the largest reported positions include MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$74.6M), SAMLYN CAPITAL, LLC (US$47.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- MONTANOVA CAPITAL, LLC 4.78M sh · $147.26M · Q2 2026
- Siren, L.L.C. 2.42M sh · $74.62M · Q2 2026
- SAMLYN CAPITAL, LLC 1.55M sh · $47.70M · Q2 2026
- Soleus Capital Management, L.P. 1.17M sh · $36.03M · Q2 2026
- Sofinnova Investments, Inc. 945.69K sh · $29.16M · Q2 2026
- Parkman Healthcare Partners LLC 919.27K sh · $28.34M · Q2 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $26.05M · Q2 2026
- Logos Global Management LP 650.00K sh · $20.04M · Q2 2026
- Ikarian Capital, LLC 504.56K sh · $15.56M · Q2 2026
- Decheng Capital LLC 464.78K sh · $14.33M · Q2 2026
- DAFNA Capital Management LLC 441.83K sh · $13.62M · Q2 2026
- Patient Square Capital LP 355.80K sh · $10.97M · Q2 2026
More on GILEAD SCIENCES, INC.
FAQ
How long has GILEAD SCIENCES, INC. held RCUS?
GILEAD SCIENCES, INC. has disclosed RCUS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is GILEAD SCIENCES, INC.'s current position in RCUS?
As of Q3 2026, GILEAD SCIENCES, INC. holds 31.42M shares of RCUS (ARCUS BIOSCIENCES INC), valued at $811.70M, representing 55.45% of its reported portfolio and ranking #1.
Has GILEAD SCIENCES, INC. been buying or selling RCUS?
In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in RCUS. The position peaked in Q2 2026 at 31.42M shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include MONTANOVA CAPITAL, LLC, Siren, L.L.C., SAMLYN CAPITAL, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.